Tempest Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Tempest Therapeutics has a total shareholder equity of $822.0K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $10.7M and $9.9M respectively.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	n/a
Cash	US$1.81m
Equity	US$822.00k
Total liabilities	US$9.93m
Total assets	US$10.75m

Recent financial health updates

Recent updates

Seeking Alpha • Aug 15

Tempest Therapeutics GAAP EPS of -$0.79

Tempest Therapeutics press release (NASDAQ:TPST): Q2 GAAP EPS of -$0.79. Tempest ended the second quarter of 2022 with $51.6M in cash and cash equivalents, compared to $51.8M at Dec. 31, 2021. The decrease was primarily due to cash used in operations of $15.5M offset by proceeds from the PIPE financing of $14.5M (net of issuance costs).

Seeking Alpha • Jan 04

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Tempest Therapeutics is a clinical-stage biotech developing small molecule therapy to treat cancer. CEO Stephen Brady joined us to discuss clinical studies, partnering with Roche and how he thinks about licensing and M&A. Allowing the immune system to do its job; biotech investing trends.

Financial Position Analysis

Short Term Liabilities: TPST's short term assets ($2.4M) do not cover its short term liabilities ($3.3M).

Long Term Liabilities: TPST's short term assets ($2.4M) do not cover its long term liabilities ($6.6M).

Debt to Equity History and Analysis

Debt Level: TPST is debt free.

Reducing Debt: TPST has no debt compared to 5 years ago when its debt to equity ratio was 116.9%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TPST has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: TPST is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/19 03:47
End of Day Share Price	2026/06/18 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tempest Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joseph Pantginis	H.C. Wainwright & Co.
Maurice Raycroft	Jefferies LLC
Aydin Huseynov	Ladenburg Thalmann & Company

Tempest Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

Tempest Therapeutics, Inc. Receives Deficiency Letter from Nasdaq

Tempest Therapeutics Receives Notice of Non -Compliance with Nasdaq Listing Rules

Tempest Therapeutics Receives Nasdaq Non-Compliance Letter Regarding Minimum Bid Price Requirement

Tempest Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

Recent updates

Tempest Therapeutics, Inc. Announces Directorate Appointments Effective June 4, 2026

Tempest Therapeutics, Inc. Receives Deficiency Letter from Nasdaq

Tempest Therapeutics, Inc. Appoints Andrew Fang, Ph.D. as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors

New minor risk - Share price stability

Tempest Therapeutics, Inc. Announces Interim Results from Ongoing RedeEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Tempest Therapeutics, Inc. Announces Board and Executive Changes Effective February 3, 2026

Tempest Therapeutics Receives Notice of Non -Compliance with Nasdaq Listing Rules

Tempest Therapeutics, Inc., Annual General Meeting, Dec 31, 2025

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.249315 million.

New major risk - Revenue and earnings growth

Tempest Therapeutics, Inc. Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.618416 million.

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

New minor risk - Share price stability

Price target decreased by 51% to US$9.50

Fda Study May Proceed Notice Received for Phase 2 Trial of Tpst-1495 for the Treatment of Familial Adenomatous Polyposis (Fap)

Tempest Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation (FTD) to Amezalpat (TPST-1120)

Tempest Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Therapeutics Receives Nasdaq Non-Compliance Letter Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Financial position

Tempest Therapeutics, Inc. Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Insufficient new directors

Tempest Announces Successful End-Of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

New major risk - Share price stability

New major risk - Financial position

CEO, President & Director recently bought US$74k worth of stock

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $205 million.

Tempest Unveils New Survival Data for Amezalpat in Randomized First-Line Hcc Study Demonstrating Six-Month Improvement over Control Arm

New major risk - Share price stability

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

Tempest Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting

Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types

New major risk - Shareholder dilution

New major risk - Negative shareholders equity

Price target increased by 26% to US$19.67

Tempest Therapeutics, Inc. Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest Therapeutics, Inc. Announces Expanded Role for Sam Whiting as Chief Medical Officer and Head of Research and Development

High number of new and inexperienced directors

Tempest Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

Tempest Therapeutics, Inc. Announces Executive Changes

Price target decreased by 18% to US$15.67

New major risk - Market cap size

Tempest Therapeutics, Inc. to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Price target increased by 16% to US$19.00

No independent directors